Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genkyotex
Saint-Julien-en-Genevois, Auvergne-Rhône-Alpes, Francegenkyotex.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Genkyotex developed first-in-class small molecule inhibitors targeting NADPH oxidase enzymes (NOX). Its lead candidate, setanaxib (formerly GKT831), advanced to Phase 2 clinical trials for fibrotic and inflammatory diseases. The company demonstrated proof-of-concept in primary biliary cholangitis and explored additional indications such as diabetic nephropathy and idiopathic pulmonary fibrosis[3][4][5].
- Therapeutic areas
- NephrologyGastroenterologyPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Genkyotex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genkyotex.